Verschoor AJ, Bovee JVMG, Mastboom MJL, Sander Dijkstra PD, Van De Sande MAJ, Gelderblom H. Incidence and demographics of giant cell tumor of bone in The Netherlands: first nationwide Pathology Registry Study. Acta Orthop England. 2018;89:570–4.
Google Scholar
CDM F, Bridge JA, MF HPCW, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC; 2013.
Google Scholar
Branstetter DG, Nelson SD, Manivel JC, Blay J-Y, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res United States. 2012;18:4415–24.
CAS
Google Scholar
McCarthy CL, Gibbons CLMH, Bradley KM, Hassan AB, Giele H, Athanasou NA. Giant cell tumour of the distal radius/ulna: response to pre-operative treatment with short-term denosumab. Clin Sarcoma Res England. 2017;7:19.
Google Scholar
Kitazawa R, Haraguchi R, Fukushima M, Kitazawa S. Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion. Histochem Cell Biol Germany. 2018;149:405–15.
CAS
Google Scholar
Lipplaa A, Kroep JR, van der Heijden L, Jutte PC, Hogendoorn PCW, Dijkstra S, et al. Adjuvant zoledronic acid in high-risk giant cell tumor of bone: a multicenter randomized phase II trial. Oncologist United States. 2019;24:889–e421.
CAS
Google Scholar
Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer England. 2010;10:462.
Google Scholar
Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int United States. 2004;75:71–7.
CAS
Google Scholar
Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, et al. Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World J Surg Oncol England. 2018;16:191.
Google Scholar
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol England. 2010;11:275–80.
CAS
Google Scholar
von Borstel D, Taguibao RA, Strle NA, Burns JE. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skelet Radiol Germany. 2017;46:571–8.
Google Scholar
Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol Canada. 2013;20:e442–7.
CAS
Google Scholar
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res United States. 2011;469:591–9.
Google Scholar
Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SPD, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol United States. 2015;22:2860–8.
Google Scholar
Veng C, Jørgensen PH, Krog-Mikkelsen I, Stilling M. Measurement of bone mineral density as an efficacy marker in denosumab treatment of giant cell tumour of bone. BMJ Case Rep. 2017;2017:bcr2017220369.
Chawla S, Blay J-Y, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol England. 2019;20:1719–29.
CAS
Google Scholar
Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am United States. 1987;69:106–14.
CAS
Google Scholar
Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT-J France. 2017;3:54.
Google Scholar
Takeuchi A, Tsuchiya H, Niu X, Ueda T, Jeon D-G, Wang EHM, et al. The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group. J Orthop Sci Japan. 2011;16:196–202.
Google Scholar
Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GRJ. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics United States. 2013;33:197–211.
Google Scholar
Hakozaki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K, et al. Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. Diagn Pathol England. 2014;9:111.
Google Scholar
Matcuk GRJ, Patel DB, Schein AJ, White EA, Menendez LR. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skelet Radiol Germany. 2015;44:1027–31.
Google Scholar
Gaston CL, Grimer RJ, Parry M, Stacchiotti S, Dei Tos AP, Gelderblom H, et al. Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clin Sarcoma Res [Internet] England. 2016;6:15. Available from: http://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-016-0056-0.
Medellin MR, Fujiwara T, Tillman RM, Jeys LM, Gregory J, Stevenson JD, et al. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone Joint J England. 2018;100-B:1626–32.
CAS
Google Scholar
Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer England. 2016;59:1–12.
CAS
Google Scholar
Osaka E, Okamura Y, Yoshida Y, Sugitani M, Tokuhashi Y. Intra-articular ectopic ossification associated with denosumab administration for giant cell tumor of bone with intra-articular pathological fracture. J Orthop Sci Japan. 2019;24:558–62.
Google Scholar
Yi J, Lee YH, Kim SK, Kim SH, Song H-T, Shin K-H, et al. Response evaluation of giant-cell tumor of bone treated by denosumab: histogram and texture analysis of CT images. J Orthop Sci Japan. 2018;23:570–7.
Google Scholar
Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol Off J Eur Soc Med Oncol England. 2015;26:2149–54.
CAS
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer England. 2009;45:228–47.
CAS
Google Scholar
Egbert RC, Folsom R, Bell J, Rajani R. Denosumab therapy for giant cell tumor of bone pulmonary metastasis. Case Rep Orthop. 2017;2017:2302597.
Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer England. 2017;76:118–24.
CAS
Google Scholar
Yamagishi T, Kawashima H, Ogose A, Sasaki T, Hotta T, Inagawa S, et al. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: a case report. Oncol Lett Greece. 2016;11:243–6.
Google Scholar
Oguro S, Okuda S, Sugiura H, Matsumoto S, Sasaki A, Susa M, et al. Giant cell tumors of the bone: changes in image features after denosumab administration. Magn Reson Med Sci Japan. 2018;17:325–30.
CAS
Google Scholar
Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques. Radiology United States. 2012;265:340–56.
Google Scholar
van der Heijden L, Dijkstra PDS, Blay J-Y, Gelderblom H. Giant cell tumour of bone in the denosumab era. Eur J Cancer England. 2017;77:75–83.
Google Scholar
Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur J Radiol Ireland. 2000;34:229–46.
CAS
Google Scholar
van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology United States. 1998;208:821–8.
Google Scholar
Satcher RL, Ravi V, Wang W-L, Oates S. Postpartum treatment of metastatic recurrent giant cell tumor of capitate bone of wrist. Am J Orthop (belle Mead NJ) United States. 2017;46:E269–75.
Google Scholar
Ross AE, Bojescul JA, Kuklo TR. Giant cell tumor: a case report of recurrence during pregnancy. Spine (Phila Pa 1976) United States. 2005;30:E332–5.
Google Scholar
Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D, et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol United States. 2013;42:27–40.
CAS
Google Scholar
Okamatsu N, Sakai N, Karakawa A, Kouyama N, Sato Y, Inagaki K, et al. Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochem Biophys Res Commun United States. 2017;491:614–21.
CAS
Google Scholar
Boyce RW, Varela A, Chouinard L, Bussiere JL, Chellman GJ, Ominsky MS, et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone United States. 2014;64:314–25.
CAS
Google Scholar
Zhang Y, Ilaslan H, Bauer TW. Giant cell tumor of bone: imaging and histology changes after denosumab treatment: Comment on: von Borstel D, Taguibao RA, Strle NA, Burns JE. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery. Skelet Radiol Germany. 2017:961–2.
Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol England. 2016;69:240–7.
CAS
Google Scholar
Akaike K, Suehara Y, Takagi T, Kaneko K, Saito T. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab. Skelet Radiol Germany. 2014;43:1767–72.
Google Scholar
Park S-Y, Lee MH, Lee JS, Song JS, Chung HW. Ossified soft tissue recurrence of giant cell tumor of the bone: four case reports with follow-up radiographs, CT, ultrasound, and MR images. Skelet Radiol Germany. 2014;43:1457–63.
Google Scholar
Cooper KL, Beabout JW, Dahlin DC. Giant cell tumor: ossification in soft-tissue implants. Radiology United States. 1984;153:597–602.
CAS
Google Scholar
Ehara S, Nishida J, Abe M, Kawata Y, Saitoh H, Kattapuram SV. Ossified soft tissue recurrence of giant cell tumor of bone. Clin Imaging United States. 1992;16:168–71.
CAS
Google Scholar
Teot LA, O’Keefe RJ, Rosier RN, O’Connell JX, Fox EJ, Hicks DG. Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation. Hum Pathol United States. 1996;27:625–32.
CAS
Google Scholar
Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer United States. 2003;97:2520–9.
Google Scholar
Domovitov S V, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol. United States; 2010;17:694–701.
Aponte-Tinao LA, Piuzzi NS, Roitman P, Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clin Orthop Relat Res United States. 2015;473:3050–5.
Google Scholar
Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C. Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab. Jpn J Clin Oncol England. 2017;47:1090–6.
Google Scholar
Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat United States. 2019;18:1533033819840000.
Google Scholar
Grote HJ, Braun M, Kalinski T, Pomjanski N, Back W, Bleyl U, et al. Spontaneous malignant transformation of conventional giant cell tumor. Skelet Radiol Germany. 2004;33:169–75.
CAS
Google Scholar
Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol United States. 2016;40:72–80.
Google Scholar
Wu C-C, Hsieh P-P. Denosumab-treated giant cell tumor of the bone mimicking low-grade central osteosarcoma. J Pathol Transl Med Korea (South). 2018;52:133–5.
Google Scholar